Select GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, albiglutide) actively reduce cardiovascular events, while DPP-4 inhibitors are safe but do not provide cardiovascular benefit.
4 GLP-1 RAs reduce MACELiraglutide, semaglutide, albiglutide, and dulaglutide all reduce major adverse cardiovascular events in diabetic patients with CV disease
What the researchers found
GLP-1 RAs (liraglutide, semaglutide, albiglutide, dulaglutide) reduce MACE in T2DM patients with CV disease, while DPP-4 inhibitors show CV safety but no MACE benefit, with saxagliptin increasing HF risk.
Why it matters
Cardiologists increasingly manage diabetes medications for cardiovascular risk reduction. Understanding which incretin drugs provide heart protection — and which do not — directly impacts patient outcomes.
The numbers in context
Liraglutide, semaglutide, albiglutide, dulaglutide reduce MACE; saxagliptin increases HF risk; sitagliptin and linagliptin HF-neutral
How the study worked
Narrative review of cardiovascular outcome trials for DPP-4 inhibitors and GLP-1 receptor agonists, written for the general cardiologist audience.
Who was studied
Type 2 diabetes patients with established cardiovascular disease
What this study cannot tell us
Review without new data; CV benefit shown in high-risk patients — may not apply to lower-risk populations; not all GLP-1 RAs tested in dedicated CV outcome trials.
How to read the evidence
Based on multiple large randomized cardiovascular outcome trials — the highest level of clinical evidence available.
When this study was published
Published in 2020; GLP-1 RA cardiovascular benefits are now firmly established in treatment guidelines worldwide.
The bigger picture
This review marks the shift in diabetes care from "do no harm" (DPP-4i safety) to "actively protect" (GLP-1 RA efficacy), making cardiovascular benefit a key drug selection criterion.
Questions still open
- Should all T2DM patients with cardiovascular disease receive a GLP-1 RA regardless of glycemic need?
- Why do GLP-1 RAs provide CV benefit while DPP-4 inhibitors do not, despite both working through GLP-1?
- Will newer GLP-1 RAs show even greater cardiovascular protection?
Common questions
Do diabetes drugs protect the heart?
What is the difference between GLP-1 drugs and DPP-4 inhibitors?
Read the original research
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.
Current cardiology reports, 22(10), 105
Citation
Patel, Kershaw V; Sarraju, Ashish; Neeland, Ian J; McGuire, Darren K. (2020). Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.. Current cardiology reports, 22(10), 105. https://doi.org/10.1007/s11886-020-01355-5